ArticleRenal failure2023
Asprosin is positively associated with metabolic syndrome in hemodialysis patients: a cross-sectional study.
Article in Renal failure, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed.
- Serum asprosin levels in patients with rheumatoid arthritis: An exploratory cross-sectional study.Medicine · 2026Observational
- Expression of asprosin and OLFR734 in reproductive tissues of polycystic ovary syndrome mice: insights into metabolic and reproductive dysfunction.Cell and tissue research · 2026Article
- Chemerin and Asprosin as Promising Biomarkers of Metabolic Syndrome: A Scoping Review.Current obesity reports · 2025Article
- Elevated serum asprosin and ANGPTL8 gene expression as novel biomarkers for the diagnosis and prognosis of acute coronary syndrome.Frontiers in cardiovascular medicine · 2025Article
- Association analysis between serum asprosin and metabolic characteristics, Complications in type 2 diabetic patients with different durations.Journal of diabetes investigation · 2024Article
- Oxidative Stress and Asprosin Levels in Type 2 Diabetic Patients with Good and Poor Glycemic Control.Biomolecules · 2024Article
- ROC curve analysis: a useful statistic multi-tool in the research of nephrology.International urology and nephrology · 2024Review
- The association of plasma asprosin with anthropometric and metabolic parameters in Korean children and adolescents.Frontiers in endocrinology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionMetabolic syndrome (MS) has a high prevalence in hemodialysis patients. High asprosin levels are associated with the accumulation of adiposity and an increase in body weight, which may drive the development of this syndrome. The relationship between asprosin and MS in patients on hemodialysis has not been investigated. MATERIALS AND
methodsWe enrolled hemodialysis patients at the hemodialysis center of one hospital in May 2021. MS was defined by the International Diabetes Federation. Fasting serum asprosin levels were measured. ROC curve, multivariate logistic regression and Spearman's rank correlation analyses were performed.
resultsIn total, 134 patients were included, with 51 with MS and 83 without MS. Among the patients with MS, there was a significantly higher proportion of women (54.9%), prevalence of DM (
conclusionsFasting serum asprosin is positively correlated with MS and could be an independent risk factor for MS in hemodialysis patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.